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Abstract
Complement alternative pathway dysregulation seems to be the pathophysiological basis of Dense
Deposit Disease (DDD). Here, we describe a monoclonal anti-factor H (FH) autoantibody in a woman
diagnosed with DDD with a monoclonal gammapathy. Enzyme-linked immunosorbent assays evi-
denced the presence of anti-FH antibodies in the patient’s serum and showed that they were
associated with the monoclonal IgG-k fraction. These autoantibodies recognize the N-terminal
region of FH and interfere with its regulatory function. In summary, in the DDD patient described
here, the activation of complement alternative pathway was favoured by the presence of anti-FH
autoantibodies that recognize the regulatory region of this protein and impede its function and
which could ultimately cause the glomerulopathy.
Keywords: anti-factor H autoantibodies; complement; dense deposit disease; monoclonal gammapathy
Background
Dense Deposit Disease (DDD) patients have evidence of com-
plement alternative pathway (AP) dysregulation as reflected
by low C3 levels in serum [1–4]. This uncontrolled systemic
activation of AP seems to be the pathophysiological basis of
the disease. The AP is spontaneously activated at low levels
in normal conditions and needs to be strictly controlled by a
number of regulators, the most important being comple-
ment factor H (FH).
FH is a glycoprotein composed of 20 homologous short
consensus repeats (SCRs). The protein includes different inter-
action sites for C3b and polyanions, with different functional
domains at the N- and C-terminal regions of the molecule [3].
FH inhibits the formation and accelerates the decay of the
AP C3 convertase and also serves as cofactor for the factor
I (FI)-mediated inactivation of C3b.
More than 80% of DDD cases are associated with C3 neph-
ritic factor (C3NeF). Recently, an autoantibody against factor
B with similar effect on C3 convertase has been described [5].
Some of the remaining cases are associated with FH deficien-
cies or mutations that lead to continuous activation of the AP
[1, 6]. So far, two cases of DDD associated with FH autoanti-
bodies have been described. One of these was a monoclonal
k light chain dimer which prevented fluid-phase regulation of
the C3 convertase by blocking FH cofactor activity [7]. The
other case showed monoclonal anti-FH antibodies without
determining their impact on protein function [8].
Here, we present the third case of DDD in association
with anti-FH autoantibodies, which inhibit FH function
and cause a systemic AP activation leading to the glomer-
ular pathology.
Case report
The patient was a 74-year-old woman admitted to the hos-
pital due to general oedema and macrohaematuria. On
physical examination, the patient showed mucocutaneous
paleness, high arterial blood pressure (199/73 mmHg) and
general oedema.
Laboratory findings revealed acute renal failure (serum
creatinine 1.8 mg/dL, urea 183 mg/dL), low total protein
and albumin levels and anaemia. A monoclonal IgG-k was
detected in the serum. Nephrotic range proteinuria (5.26
g per 24 h) with Bence Jones and haematuria (30–50 red
blood cells per field) were observed. Bone marrow aspi-
rate presented 9% plasma cells and cryoglobulins re-
sulted negative.
Renal biopsy revealed glomeruli with mesangial expan-
sion and immune deposits distributed in the mesangium
and in the peripheral capillary walls in a subendothelial pat-
tern. These deposits were strongly periodic-acid-schiff pos-
itive. Immunohistochemistry techniques were negative for
detecting kappa and lambda light chains and Congo red
staining was also negative. In the ultrastructural study, there
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were localized fibrillar deposits of an approximate diameter
of 27 nm in the mesangium and capillary walls. On the other
hand, irregular and discontinuous thickening of glomerular
basement membranes because of an electron-dense and
homogeneous deposit was observed (Figure 1A).
In summary, the patient was diagnosed with fibrillar glo-
merulonephritis and ultrastructural findings were compatible
with DDD.
At this point, the patient’s serum was remitted to Hospital
La Paz to extend the immunological study.
Serological study showed normal immunoglobulin and C4
levels but reduced C3 (Supplementary Table 1), which was
suggestive of complement AP activation. Immunofixation
of serum identified IgG-k monoclonal gammapathy with
residual IgG-j. C3NeF haemolytic assay was performed
and resulted negative. Complement FH measurement by
Enzyme-linked immunosorbent assay (ELISA) revealed re-
duced levels of this protein and anti-FH autoantibodies were
detected in the patient’s serum and in the patient’s purified
IgG fraction. Anti-FH activity was confirmed by western blot
analysis and another reactivity of the IgG fraction was ob-
served (Figure 1B, lane 1).
The light chain isotype of the autoantibody was deter-
mined by ELISA, and the anti-FH activity was associated
mainly with monoclonal IgG-k (Figure 1C).
To determine which part of the FH molecule is recognized
by the patient’s IgG, a competition ELISA with immobilized
FH pre-incubated with various anti-FH antibodies was made
and it indicated that the autoantibody binds to SCRs 1–4
of FH. Another ELISA assay also showed that the patient’s
IgG binds to recombinant factor H-like protein 1 (CFHL1), a
splicing variant of FH which comprises SCRs 1–7 of the
molecule (Figure 2 A and B). This was confirmed by western
blot analysis of the patient’s IgG (not shown).
As the N-terminal region of the FH molecule is where the
regulator domain is, the effect of the patient’s antibody on
fluid-phase cofactor activity of FH was tested. In the pres-
ence of FH and patient’s IgG, an absence of C3b degradation
by FI was observed (Figure 2C).
Another serum protein recognized by the patient’s IgG
was plasminogen, identified by mass spectrometry from
a Coomassie stained-gel band, after 8% sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS–PAGE)
(Proteomics Unit, Universidad Complutense, Madrid, Spain).
Anti-plasminogen activity was then tested in the purified
IgG and in patient’s serum by ELISA and western blot
(Supplementary Figure 1).
Because of the probable association of monoclonal gam-
mapathy with two glomerular diseases, the patient started
treatment with cyclophosphamide and dexamethasone.
Discussion
This is the third report of a patient with DDD and FH autoanti-
bodies, the second demonstrating blocking of FH function by
autoantibodies.
The patient reported here had a monoclonal IgG-k
that was associated with the anti-FH activity. When
the patient started her treatment, monoclonal IgG titres
diminished and so did FH autoantibodies. Renal function
improved and C3 and FH serum levels achieved normal
values (Supplementary Table 1).
Fig. 1. (A) High-power microscopic view shows the segmental irregular distribution of the ribbon-like thickenings of the glomerular basement membranes
by intramembranous highly electron-dense deposits. (B) Western blot. SDS–PAGE carried out with IgG depleted normal human serum (NHS) in well 1 and 3
(corresponding to lane 1 and 3 in the figure) and with purified FH in well 2. After transfer, lanes 1 and 2 were revealed with IgG purified from the patient and
lane 3 with a polyclonal anti-FH antibody that identifies FH and some Complement Factor H-related proteins (CFHR) in NHS. (C) Anti-FH antibody light chain
isotype determination by ELISA assay. Anti kappa, anti-human j light chain antibody; anti lambda, anti-human k light chain antibody; inv. Dil, serum
inversal dilution; CFHR1, complement Factor H-related protein 1.
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The patient’s antibodies recognized the regulatory region
of FH and they blocked FH cofactor activity for FI. As anti-
bodies impeded FH function, complement AP was constitu-
tively activated. The effect of these autoantibodies on FH
function seems to be analogous to a mutation in SCR4 de-
scribed previously in which cell-binding activity was normal
but complement control was defective [9].
The patient’s antibodies prevented fluid-phase FH func-
tions, and this inhibitory effect promotes systemic comple-
ment activation, diminishes C3 serum levels, and C3 and
terminal components of complement cascade deposition
on the kidney. FH autoantibodies are relatively frequent
in atypical haemolytic uraemic syndrome, where they are
directed to SCRs 19–20, impairing FH binding to surface-
bound C3b and cell membranes and limiting its capacity
to protect cells from complement lysis. This causes a lo-
calized damage on the surface of renal endothelial cells
by inadequate protection from complement activation, not
the systemic activation seen in DDD.
The patient’s autoantibodies also recognize plasminogen,
whose presentation could be related with anti-FH autoanti-
bodies. Numerous pathogens have surface proteins that bind
both host proteins to avoid elimination by complement dur-
ing the innate immune response [10]. Thus, complement
regulators and other proteins attached to the pathogen’s
surface would be recognized as antigens and the host would
develop antibodies against these self-proteins.
Supplementary data
Supplementary data are available online at http://
ckj.oxfordjournals.org.
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